<DOC>
	<DOCNO>NCT00856024</DOCNO>
	<brief_summary>This Phase 4 , retrospective observational , multicenter , national ( Brazil ) , open , noncomparative , nonrandomized study , visit . This study conduct accordance Good Clinical Practices . The procedure review medical record patient already complete 12 week treatment chronic hepatitis C peginterferon alfa-2b ribavirin . This review take place subject sign informed consent form authorize collection data . The collection data virological response Week 12 collect prospectively review medical record subject complete entire treatment follow-up period .</brief_summary>
	<brief_title>ATHENAS - Retrospective Study Compliance Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin Brazil ( P05632 )</brief_title>
	<detailed_description>This Phase 4 , retrospective observational , multicenter , national ( Brazil ) , open , noncomparative , nonrandomized study , visit . This study conduct accordance Good Clinical Practices . The procedure review medical record patient already complete 12 week treatment chronic hepatitis C peginterferon alfa-2b ribavirin . This review take place subject sign informed consent form authorize collection data . The physician filling case report form information contain medical record . Any dose reduction and/or dose take period report case report form . The collection data virological response Week 12 ( virological response end treatment sustain virological response follow-up period ) collect prospectively review medical record subject complete entire treatment follow-up period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must confirm his/her willingness participate study , inform aspect pertinent his/her decision participate , sign date informed consent form ( ICF ) approve Institutional Review Board / Independent Ethics Committee Research ( IRB/IEC ) . Adult patient 18 year old . Must diagnosis chronic hepatitis C confirm positive qualitative quantitative PCR ( polymerase chain reaction ) perform prior initiation patient 's treatment . This result shall document patient 's record . Must complete 12 week treatment peginterferon alfa2b ribavirin . Patients start treatment chronic hepatitis C year 2008 later . Does confirm his/her willing participate study refuse sign informed consent form . Did start treatment peginterferon alfa2b ribavirin . Patients less 12 week treatment peginterferon alfa2b ribavirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>